John A Wells
Overview
Explore the profile of John A Wells including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1381
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wong T, Haskova Z, Asik K, Baumal C, Csaky K, Eter N, et al.
Ophthalmology
. 2023 Dec;
131(6):708-723.
PMID: 38158159
Purpose: To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab according to a personalized treat-and-extend (T&E)-based...
2.
Khanani A, Patel S, Gonzalez V, Moon S, Jaffe G, Wells J, et al.
Ophthalmol Sci
. 2022 Oct;
1(3):100040.
PMID: 36247818
Purpose: To evaluate the safety and preliminary efficacy of THR-687 in patients with center-involved diabetic macular edema (DME). Design: Phase 1, open-label, multicenter, 3 + 3 dose-escalation study with 3-month...
3.
Wykoff C, Abreu F, Adamis A, Basu K, Eichenbaum D, Haskova Z, et al.
Lancet
. 2022 Jan;
399(10326):741-755.
PMID: 35085503
Background: To reduce treatment burden and optimise patient outcomes in diabetic macular oedema, we present 1-year results from two phase 3 trials of faricimab, a novel angiopoietin-2 and vascular endothelial...
4.
Sun J, Maturi R, Boyer D, Wells J, Gonzalez V, Tansley R, et al.
Ophthalmol Retina
. 2019 Dec;
3(12):1107-1109.
PMID: 31810575
No abstract available.
5.
Wells J, Gonzales C, Berger B, Gonzalez V, Sippy B, Burian G
Ophthalmic Surg Lasers Imaging Retina
. 2018 May;
49(5):336-345.
PMID: 29772044
Background And Objective: This phase 1 study evaluated the safety and tolerability of single intravitreous injections (IVIs) of ICON-1 (Iconic Therapeutics, South San Francisco, CA) in patients with neovascular age-related...
6.
Jampol L, Glassman A, Liu D, Aiello L, Bressler N, Duh E, et al.
Ophthalmology
. 2018 Mar;
125(7):1054-1063.
PMID: 29525602
Purpose: To assess systemic vascular endothelial growth factor (VEGF)-A levels after treatment with intravitreous aflibercept, bevacizumab, or ranibizumab. Design: Comparative-effectiveness trial with participants randomly assigned to 2 mg aflibercept, 1.25...
7.
Bressler S, Liu D, Glassman A, Blodi B, Castellarin A, Jampol L, et al.
JAMA Ophthalmol
. 2017 Apr;
135(6):558-568.
PMID: 28448655
Importance: Anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) favorably affects diabetic retinopathy (DR) improvement and worsening. It is unknown whether these effects differ across anti-VEGF agents....
8.
Wells J, Glassman A, Bressler N, Ayala A, Jampol L
Ophthalmology
. 2017 Mar;
124(4):e38-e39.
PMID: 28335949
No abstract available.
9.
McCracken D, Higginbotham R, Boulter J, Liu Y, Wells J, Halani S, et al.
Neurosurgery
. 2017 Mar;
80(6):957-966.
PMID: 28327941
Background: Sphenoid wing meningiomas (SWMs) can encase arteries of the circle of Willis, increasing their susceptibility to intraoperative vascular injury and severe ischemic complications. Objective: To demonstrate the effect of...
10.
Wells J, Glassman A, Jampol L, Ayala A, Bressler N
Ophthalmology
. 2017 Feb;
124(3):e26-e27.
PMID: 28219510
No abstract available.